惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Hugging Face - Blog
Hugging Face - Blog
云风的 BLOG
云风的 BLOG
Google DeepMind News
Google DeepMind News
美团技术团队
J
Java Code Geeks
V
V2EX
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
The Cloudflare Blog
宝玉的分享
宝玉的分享
博客园 - Franky
Y
Y Combinator Blog
爱范儿
爱范儿
H
Help Net Security
腾讯CDC
G
Google Developers Blog
B
Blog RSS Feed
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
阮一峰的网络日志
阮一峰的网络日志
罗磊的独立博客
V
Visual Studio Blog
The GitHub Blog
The GitHub Blog
博客园_首页
C
Check Point Blog
博客园 - 三生石上(FineUI控件)

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Vitrolife AB (publ) (VTRLY) Q1 2026 Earnings Call Transcript
2026-04-24 · via All Articles on Seeking Alpha

Vitrolife AB (publ) (VTRLY) Q1 2026 Earnings Call April 23, 2026 4:00 AM EDT

Company Participants

Bronwyn Brophy - CEO & President
Par Ihrskog - Chief Financial Officer

Conference Call Participants

Ulrik Trattner - DNB Carnegie, Research Division
Jakob Lembke - SEB, Research Division
Ludvig Lundgren - Nordea Markets, Research Division
Sten Gustafsson - ABG Sundal Collier Holding ASA, Research Division
Filip Einarsson - Redeye AB, Research Division
Filip Wiberg - Pareto Securities AS, Research Division

Presentation

Operator

Welcome to Vitrolife Q1 2026 Earnings Call. [Operator Instructions]

Now I will hand the conference over to CEO, Bronwyn Brophy; and CFO, Par Ihrskog. Please go ahead.

Bronwyn Brophy
CEO & President

Good morning, everyone, and welcome to the Vitrolife Group Q1 2026 Earnings Call. Thank you for dialing in. I am joined by Par Ihrskog, the CFO of the Vitrolife Group. And I'd like to start this morning and today's presentation by providing you with an update on the latest dynamics that we are seeing in the reproductive health market. I've broken this down into 3 key areas. Markets or regions, customers and competitors. So let's start with the markets.

What we're seeing is European IVF cycles are remaining stable. We see cycle growth rates starting to increase in North America after a slow start to the year. And what I would point out is we're starting to see an increased seasonality there, whereby January is a particularly slow month and the growth tends to accelerate as the calendar year progresses.

Middle East IVF cycle activity is significantly down as one would reasonably expect given the geopolitical situation. In APAC, the markets are performing stronger than expected, but I would like to point out that Q1 2025 was exceptionally low. And then the other dynamic that we are seeing is an increase in regulation of genetic testing. We welcome this